The blog says that HNK (the purported antidepressant) is a known metabolite of ketamine, but then claims:<p>&gt; However, getting regulatory approval for such a study, which would technically (as far as I know) be a first-in-man trial of HNK, might take a long time.<p>I don&#x27;t understand this. We already know that when we give ketamine to patients they are exposed to HNK. Is there a real risk that it is more dangerous in isolation?<p>Even if caution is required in the first patients, why do we accept as normal that developing treatments like this should involve years of waiting for bureaucratic approval?